Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Thallion Pharmaceuticals Inc V.TLN

TSXV:TLN - Post Discussion

View:
Post by BioLogic on May 23, 2012 2:36pm

My Take

My take is that if LFB stays the course and continues development and commits to a larger Phase 2b or Phase 3 (even better) this is a huge opportunity to buy more stock. If they bail on the program this goes straight into the toilet. Time will tell. All depends on whether they are surprised by the lack of efficacy signal, or whether they knew it was underpowered and hoped for but didn't expect anything different.
Comment by dreamer05 on May 24, 2012 12:28pm
Her is my take.  LFD has already got through 2 phrases of the drug. They must have some datas concerning the effecacity of the drug. How to interprete it is another story. I know for fact is this drug is safe  and it works ( effactive ) on mice.  True, things works on mice  does not mean it works on humans. One way to find out is to give it to all E-coli affected patients ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities